
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge
By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly on Thursday downplayed CVS Health (NYSE:CVS)’s decision to drop the company’s obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell more than 10%. CVS said its pharmacy benefit management unit, which is the largest in the U.S., would drop Zepbound coverage from July 1, b ...